Literature DB >> 16291710

Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.

Brian P Kearney1, John R Sayre, John F Flaherty, Shan-Shan Chen, Sanjeev Kaul, Andrew K Cheng.   

Abstract

The drug-drug and drug-food interactions between tenofovir DF and didanosine EC were evaluated in 2 pharmacokinetic studies in healthy adult subjects. When 400 mg was dosed with tenofovir DF, mean didanosine AUC was increased by 44% to 60% following fasted or fed administration. Staggered coadministration (2 hour, fasted) of a reduced didanosine dose of 250 mg resulted in equivalent didanosine exposure, while simultaneous administration with tenofovir DF in the fasted and fed state resulted in didanosine AUCs similar to that of the reference treatment of 400 mg alone in the fasted state. These data indicate that a dose reduction of didanosine is warranted when it is used with tenofovir DF. The drug-drug-food interaction of didanosine may offer more flexible dosing of didanosine EC when it is used with tenofovir DF. Patients receiving tenofovir DF and didanosine together should be carefully monitored for safety and efficacy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291710     DOI: 10.1177/0091270005281351

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

1.  Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.

Authors:  Trevor Hawkins; Wenoah Veikley; Lucie Durand-Gasselin; Darius Babusis; Y Sunila Reddy; John F Flaherty; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 2.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.

Authors:  Douglas Barnas; Dianna Koontz; Holly Bazmi; Christian Bixby; Joseph Jemsek; John W Mellors
Journal:  Antivir Ther       Date:  2010

5.  Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy.

Authors:  A K Pau; S D Boyd
Journal:  Clin Pharmacol Ther       Date:  2010-07-28       Impact factor: 6.875

6.  Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Authors:  Alain Pruvost; Eugènia Negredo; Frédéric Théodoro; Jordi Puig; Mikaël Levi; Rafaela Ayen; Jacques Grassi; Bonaventura Clotet
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

7.  Lack of a significant drug interaction between raltegravir and tenofovir.

Authors:  Larissa A Wenning; Evan J Friedman; James T Kost; Sheila A Breidinger; Jon E Stek; Kenneth C Lasseter; Keith M Gottesdiener; Joshua Chen; Hedy Teppler; John A Wagner; Julie A Stone; Marian Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

8.  Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.

Authors:  P Costa; F Bozzano; D Fenoglio; A Beltrame; G Cenderello; A Di Biagio; G Ferrea; G Pagano; A De Maria
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

Review 9.  Nucleoside and nucleotide reverse transcriptase inhibitors in children.

Authors:  Carlo Giaquinto; Osvalda Rampon; Martina Penazzato; Federica Fregonese; Anita De Rossi; Ruggiero D'Elia
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 10.  Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.

Authors:  Santiago Moreno; Beatriz Hernández; Fernando Dronda
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.